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Brazil; 6Clinical Hospital of Porto Alegre Porto Alegre, RS, BrazilA B S T R A C TObjective: To analyze the cost-effectiveness and cost-utility of dabiga-
tran compared with warfarin in patients with nonvalvular atrial ﬁbrilla-
tion with moderate to high risk of ischemic stroke or systemic embolism
and eligible for treatment with anticoagulants. Methods: Markov-based
economic analysis was performed to estimate treatment costs and
outcomes. Epidemiological and efﬁcacy data were determined after a
critical revision of the medical literature. Unit costs were taken from
Brazilian ofﬁcial databases. Only direct medical costs were covered.
Costs and beneﬁts were discounted at a rate of 5% per year. Outcomes
were expressed as life-year (LY) and quality-adjusted life-year (QALY).
Results: Dabigatran use is cost-effective in terms of LY and QALY
considering a willingness-to-pay threshold of 3 times gross domestic
product per capita of 2010 (Brazilian real 57,048/US $24,275.74) per LYee front matter Copyright & 2015, International S
r Inc. This is an open access article under the CC
ons.org/licenses/by-nc-nd/4.0/).
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ão Paulo Brazil.and QALY saved in both analyzed perspectives (private and public
health care systems). Conclusions: Dabigatran use improves patient
survival and quality of life compared with warfarin. This represents
the best therapeutic option in terms of cost and effectiveness in the
prevention of ischemic stroke and systemic embolism in patients with
nonvalvular atrial ﬁbrillation.
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Atrial ﬁbrillation (AF) is a supraventricular arrhythmia in which
an atrial electrical activity disorder occurs, causing the atria to
lose their ability to contract, not generating atrial systole [1]. In
population studies, AF is an important risk factor for ischemic
stroke (IS), heart failure, and death [2], with a 3% to 6% annual
risk of thromboembolic complications, which is 5 to 7 times
greater than the risk in controls with a sinus rhythm [3].
The prevalence of AF is inﬂuenced by age, sex, presence of
cardiovascular disease, such as valvular disease, and risk factors
such as hypertension, diabetes, obesity, and insulin resistance
[1,4]. Brazilian data show an annual incidence below 0.1% in the
population younger than 40 years and 1.5% and 2.0% in men and
women, respectively, older than 80 years [1].More than 20% of all ISs are attributable to AF [4], thus
representing the largest single cause and one of the most
important risk factors for the occurrence of this condition in
Brazil. The incidence of IS in patients with nonvalvular atrial
ﬁbrillation (NVAF) averages 5% per year [5].
AF is related to greater stroke severity, higher mortality, worse
functional prognosis after stroke, greater recurrence, and longer
hospital stays, resulting in larger and more signiﬁcant costs to
health care systems [6].
To reduce all these risks associated with AF, it is essential to
rationally institute an anticoagulant therapy. Currently, therapy
with vitamin K antagonists, especially warfarin, is the medication
of choice for primary and secondary stroke prevention, transient
ischemic attack, and other thromboembolic events in patients
with AF at high risk for these events. This therapy, however, hasociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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to establish new anticoagulant agents that are effective, safe, and
more convenient to use.
Dabigatran etexilate is a small molecule that is rapidly
absorbed after oral administration and converted into dabigatran
acting directly by inhibiting thrombin, responsible for the con-
version of ﬁbrinogen into ﬁbrin during coagulation cascade and
preventing the development of thrombus (clot). In addition,
dabigatran has proven its efﬁcacy and safety without the need
of coagulation monitoring and dose adjustments, and does not
cause dietary restrictions for patients [8].
The objective of the present study was to determine the cost-
effectiveness and cost-utility of the use of the new oral anti-
coagulant dabigatran compared with warfarin in patients with
NVAF at risk for IS or systemic embolism and eligible for anti-
coagulant therapy.Methods
Target Population
The modeled patient population comprised adults with NVAF at risk
for IS or systemic embolism, eligible for treatment with an anti-
coagulant on the basis of CHADS and CHADSVASc scores. The
CHADS2 score is a measure of the risk of stroke in which congestive
heart failure, hypertension, an age of 75 years, and diabetes mellitus
are each assigned 1 point and previous stroke or transient ischemic
attack is assigned 2 points; the score is calculated by summing all the
points for a given patient. Themean CHADS2 score in the model was
2.1. Of patients who entered the model, 63.6% were men aged 71
years, considering the predominant prevalence of AF in this age
group, according to population-based studies [9].Study Perspective
This study was developed from the perspectives of the Brazilian
private health care system (Sistema de Saúde Suplementar [SSS])
and public health care system (Sistema Único de Saúde [SUS]).Fig. 1 – Markov mModel Structure
Markov models have two components: structure and parameters.
The “structure” refers to health states represented in the model
and the possible transitions between them. The “parameters” of
the model include the probabilities assigned to transitions
between states of health.
To estimate costs and outcomes of each treatment, a Markov
model was designed to follow patients with NVAF at risk for
clinically relevant events along the natural course of the disease
until the end of their lives. This model considered patients
transition through different health states, as shown in Fig. 1.
The primary and recurrent clinical events included were IS,
hemorrhagic stroke, transient ischemic attack (TIA), systemic
embolism (SE), acute myocardial infarction (AMI), intracranial
hemorrhage (ICH), extracranial hemorrhage, and death. Figure 1
represents the Markov model structure with the health states
considered in the analysis.
The model was evaluated within lifetime horizon (10 years).
Costs and outcomes were discounted to the present value at a
rate of 5% yearly, according to recommendations of the
Methodological Guidelines for Economic Studies Evaluation in
Health Technology Assessment, published by the Ministry of
Health [10].
Patients transition through several health states has consid-
ered relevant clinical events such as IS or ICH. Depending on the
event severity, patients may either return to the state they were
in before the event or suffer a permanent deterioration toward a
worse dependence level. In addition, patients can die as a result
of a stroke or hemorrhage, or other comorbidities. A 3-month
cycle duration was chosen because of the low probability for
patients to have more than one severe event within this period,
and it reﬂects the typical duration of temporary treatment
discontinuation due to severe hemorrhages.
The modeling analysis allows predicting clinical and eco-
nomic outcomes for a cohort of 1000 eligible patients over their
lifetime, by calculating the life-years (LYs), quality-adjusted life-
years (QALYs), and costs accumulated over this period depending
on treatment choice. LYs are calculated on the basis of average
time (in years) the patient remained alive in the model. QALYodel structure.
Table 1 – Treatment lines.
Comparison First-line
treatment
Second-line
treatment
Dabigatran vs.
warfarin
Dabigatran Acetylsalicylic acid þ
clopidogrel
Perspective: SSS Warfarin Acetylsalicylic acid þ
clopidogrel
Dabigatran vs.
warfarin
Dabigatran Acetylsalicylic acid
Perspective: SUS Warfarin Acetylsalicylic acid
SSS, Sistema de Saúde Suplementar; SUS, Sistema Único de Saúde.
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and the corresponding utility for that state (where a utility of 1
denotes full health and 0 denotes death).
Comparators
The treatments considered for patients with NVAF with risk of IS
or SE were as follows.
First-line treatment1. Dabigatran 150 mg twice a day for patients younger than 80
years and dabigatran 110 mg twice a day for patients older
than 80 years and2. warfarin 5 mg/d.
Second-line treatment1. Acetylsalicylic acid in monotherapy 162 mg/d within the SUS
perspective;2.Table 2 – Risk of event related to warfarin treatment
(rate per 100 patients/y).
Risk of ischemic stroke
CHADS score2
0 0.62
1 0.79
2 0.88
3 1.55
4 1.55
5 2.77
6 2.77
Risk of systemic embolism 0.15
Risk of transient ischemic attack 0.73
Risk of intracranial hemorrhage (hemorrhagic
transformation after ischemic stroke)
0.35
Risk of hemorrhagic stroke 0.33
Risk of extracranial hemorrhage 2.71
Risk of acute myocardial infarction 0.59
Source: RE-LY Steering Committee and Investigators and Mixed
treatment Comparison [8,9].Acetylsalicylic acid 162 mg/d combined with clopidogrel 75
mg/d within the SSS perspective.
It is worth mentioning that such medicines were used as
second-line treatment because this was the Brazilian clinical
practice when the current economic analysis was carried out.
Table 1 presents ﬁrst- and second-line treatments considered
in each comparison carried out herein.
Clinical and Safety Data
The economic model was mainly based on two studies: RE-LY [11]
and Roskell’s meta-analysis [12].
Themodel considered the risk of events (IS, SE, TIA, ICH, and AMI)
related to the treatment with warfarin. Risks concerning the compar-
ison of warfarin with the other analyzed treatment methods (dabi-
gatran used as ﬁrst-line therapy and acetylsalicylic acid combined or
not with clopidogrel used as second-line therapy) were also applied.
The risk of each event related to the treatment with warfarin is
presented in Table 2.
Relative risks concerning the comparison of warfarin with other
analyzed treatment methods are presented in Table 3. Acetylsalicylic
acid and acetylsalicylic acid associated with clopidogrel were also
analyzed because these drugs were administered after the failure of
warfarin or dabigatran as second-line therapy. It is noteworthy that
on SUS, acetylsalicylic acid associated with clopidogrel is not
incorporated for NVAF indication; for this reason, the second-line
treatment on SUS is composed of only acetylsalicylic acid.
Probabilities to develop a permanent or temporary disability
(described as independent, moderate dependent, and totally
dependent) after an event (IS) for each treatment method arerepresented in Table 4. This table also presents the probability of
mortality within up to 90 days after the event for each treatment.
The risks of fatal SE, fatal extracranial hemorrhage, and fatal
acute myocardial infarction considered in the model were 0.46%,
0.03%, and 1.11% per year, respectively [13]. This risk is the same
for both treatments (dabigatran and warfarin).
Resources Use and Treatment Costs
On a conservative basis, only direct medical costs were consid-
ered. Indirect costs related to patient productivity loss were not
included in the analysis.
Resources used for the treatment of acute events and the
follow-up of such patients after the event were deﬁned on the
basis of specialists’ opinion. Medical visits, hospitalizations,
laboratory tests, procedures, and drugs were taken into account
(for model costs, see Appendix I in Supplemental Materials found
at http://dx.doi.org/10.1016/j.vhri.2015.02.003).
For the perspective of the private health care system, costs of
medical visits, laboratory tests, and procedures were obtained
through the Brazilian Hierarchical Classiﬁcation of Medical Pro-
cedures (Classiﬁcação Brasileira Hierarquizada de Procedimentos
Médicos) and the daily hospital stay cost was extracted from the
Programa de Estudos Avançados em Administração Hospitalar e
de Sistemas de Saúde Bulletin (PROAHSA) [14,15].
For the perspective of the public health care system, these
costs were extracted from the public Brazilian database (SIGTAP:
Sistema de Gerenciamento da Tabela de Procedimentos, Medi-
camentos e OPM do SUS) [16].
All costs were collected in 2010 (base year). Total costs were
calculated by multiplying the amount of used resources by the
unit cost of the respective resources. The costs of each event
considered in the model are given in Table 5. For price conver-
sion, from Brazilian real (R$) to US dollar (US $), the average
exchange tax published by Central Bank of Brazil, from the last 60
business days to the date of this report elaboration (October 2014)
(US $1.00 equals R$ 2.35), was used.
Drugs’ unit costs were taken from the Brazilian ofﬁcial data-
base (Câmara de Regulação do Mercado de Medicamentos),
considering the ex-factory price added by 18% of value added
tax [17]. Prices of drugs used in monthly economic models are
given in Table 6.
Table 3 – Relative risk: Treatment regimens versus warfarin.
Events RR 95% CI lower 95% CI higher
Ischemic stroke
Dabigatran 0.80 0.60 1.06
Acetylsalicylic acid þ clopidogrel* 2.07 1.38 3.11
Acetylsalicylic acid* 1.62 0.99 2.65
Systemic embolism
Dabigatran 0.74 0.34 1.61
Acetylsalicylic acid þ clopidogrel* 3.57 1.52 8.36
Acetylsalicylic acid* 1.77 0.66 4.77
Transient ischemic attack
Dabigatran 0.82 0.58 1.15
Acetylsalicylic acid þ clopidogrel* 1.56 0.86 2.83
Acetylsalicylic acid* 1.56 0.86 2.83
Intracranial hemorrhage (hemorrhagic transformation after ischemic stroke)
Dabigatran 0.43 0.21 0.88
Acetylsalicylic acid þ clopidogrel* 0.53 0.19 1.45
Acetylsalicylic acid* 0.51 0.16 1.60
Hemorrhagic stroke
Dabigatran 150mg (twice a day) 0.23 0.09 0.47
Dabigatran 110mg (twice a day) 0.23 0.07 0.91
Acetylsalicylic acid þ clopidogrel* 0.84 0.06 5.24
Acetylsalicylic acid* 0.84 0.20 1.53
Extracranial hemorrhage
Dabigatran 1.05 0.83 1.33
Acetylsalicylic acid þ clopidogrel* 1.10 0.71 1.72
Acetylsalicylic acid* 1.14 0.47 2.73
Acute Myocardial infarction
Dabigatran 1.30 0.92 1.85
Acetylsalicylic acid þ clopidogrel* 1.48 0.83 2.63
Acetylsalicylic acid* 1.42 0.84 2.39
Source: Based on RE-LY Steering Committee and Investigators and Mixed treatment Comparison [8,9].
RR, relative risk; CI, Conﬁdence interval.
* Used as second-line treatment.
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The quantiﬁcation of uncertainty involved in the economic model
and the identiﬁcation of variables mostly affecting such uncertainty
are crucial to support decision making. A probabilistic sensitivity
analysis was carried out to validate the results of this evaluation
through the use of distributions, instead of the parameter values
used in the mathematical model, to establish the impact of
uncertainty of each parameter included in the study.Table 4 – State of the patient with ischemic stroke and i
Level of disability Dabigatran 150
mg (twice a day)
Dabigatran 110
mg (twice a da
Ischemic stroke (%)
Independent 58.0 32.6
Moderate dependent 14.9 39.9
Totally dependent 4.1 0.1
Mortality in 90 d 22.9 27.3
Intracranial hemorrhage (hemorrhagic transformation after ischemic str
Independent 7.8 7.8
Moderate dependent 8.8 8.8
Totally dependent 31.8 31.8
Mortality in 90 d 51.6 51.6
Source: RE-LY Steering Committee and Investigators [8,9].
* Used as second-line treatment.All costs included in the analyses were varied by 10%
considering gamma distributions. Beta distributions were used
for transition probabilities, as well as efﬁcacy and safety data. In
the probabilistic analysis, 1000 simulations (Monte Carlo second
order) were estimated for each perspective and for each outcome.
Results were evaluated and ranked as follows: quadrant 1
(incremental effectiveness 4 0 and incremental cost 4 0),
quadrant 2 (incremental effectiveness o 0 and incrementalntracranial hemorrhage (rate of 100 patients/y).
y)
Warfarin Acetylsalicylic
acid*
Acetylsalicylic acid
þ clopidogrel*
53.9 51.4 53.9
19.7 18.0 19.7
4.3 6.7 4.3
22.2 23.8 22.2
oke and hemorrhagic stroke) (%)
7.8 15.1 15.1
8.8 16.3 16.3
31.8 42.8 42.8
51.6 25.9 25.9
Table 5 – Annual cost of clinical events.
Event Cost
SUS SSS
Fatal ischemic stroke R$ 11,809.68 US $5,025.40 R$ 24,625.12 US $10,478.77
Ischemic stroke, independent R$ 2,811.67 US $1,196.46 R$ 4,327.33 US $1,841.42
Ischemic stroke, moderate disability R$ 4,469.65 US $1,901.98 R$ 16,447.50 US $6,998.94
Ischemic stroke, totally dependent R$ 6,280.25 US $2,672.45 R$ 22,982.60 US $9,779.83
Fatal embolism R$ 11,809.68 US $5,025.40 R$ 24,625.12 US $10,478.77
Nonfatal embolism R$ 11,809.68 US $5,025.40 R$ 24,625.12 US $10,478.77
Transient ischemic attack R$ 1,808.29 US $769.49 R$ 3,334.82 US $1,419.07
Fatal intracranial hemorrhage R$ 15,571.62 US $6,626.22 R$ 22,848.98 US $9,722.97
Fatal hemorrhagic stroke R$ 23,259.54 US $ 9,897.68 R$ 42,618.19 US $ 18,135.40
Hemorrhagic stroke, independent R$ 2,811.67 US $1,196.46 R$ 4,327.33 US $184,141.70
Hemorrhagic stroke, moderate disability R$ 4,469.65 US $1,901.98 R$ 16,447.50 US $6,998.94
Hemorrhagic stroke, totally independent R$ 6,280.25 US $2,672.45 R$ 22,982.60 US $9,779.83
Fatal extracranial hemorrhage R$ 1,017.89 US $433.14 R$ 2,958.41 US $1,258.90
Minor bleeding R$ 19.30 US $8.21 R$ 91.64 US $39.00
Fatal acute myocardial infarction R$ 15,530.13 US $6,608.57 R$ 37,775.73 US $16,074.78
Nonfatal acute myocardial infarction R$ 16,852.38 US $7,171.23 R$ 41,983.67 US $17,865.39
Source: Specialist panel, SIGTAP, CBHPM, and PROAHSA [11–13].
CBHPM, Classiﬁcação Brasileira Hierarquizada de Procedimentos Médicos; PROAHSA, Programa de Estudos Avançados em Administração
Hospitalar e de Sistemas de Saúde SIGTAP, Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos e OPM do SUS; SSS,
Sistema de Saúde Suplementar; SUS, Sistema Único de Saúde.
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incremental cost o 0), and quadrant 4 (incremental effectiveness
4 0 and incremental cost o 0).Results
Cost-Effectiveness and Cost-Utility Analysis
Outcomes and total costs were calculated for a lifetime horizon
(10 years). Table 7 presents effectiveness results: LY and QALY as
well as total costs throughout the time horizon.
Cost-effectiveness results were expressed in terms of incre-
mental cost per LY and QALY gained and are also given in Table 7.
In both perspectives, analyzed results indicate that treatment
with dabigatran is associated with a total cost higher than treat-
ment with warfarin. Regarding the outcomes analyzed, dabigatran
shows gains in terms of overall survival and quality of life.
Considering a threshold equal to 3 times the gross domestic
product (GDP) per capita of 2010 per QALY gained, results indicate
that the use of dabigatran is cost-effective compared with the
treatment with warfarin (3  GDP per capita ¼ R$ 57.048) in both
perspectives evaluated [18].
Clinical results are different in both perspectives because the
second-line treatment considered is different depending on theTable 6 – Drug cost items.
Drug Description
Dabigatran Pradaxa 110 and 150 mg R$
Warfarin Coumadin 5 mg R$
Acetylsalicylic acid* Bufferin Cardio 81 mg R$
Clopidogrel* Plavix 75 mg R$
Source: CMED, Câmara de Regulação do Mercado de Medicamentos—Dec
* Used as second-line treatment.perspective analyzed (SUS: acetylsalicylic acid; SSS: acetylsalicylic
acid combined with clopidogrel).
Thus, dabigatran treatment has been shown to be cost-
effective compared with warfarin treatment, with better clinical
results and an additional cost justiﬁed by the beneﬁt in terms of
overall survival and quality of life provided to the patient.Sensitivity Analysis
After varying all costs involved in the analysis by 10% by using
gamma distributions and transition probabilities, as well as
efﬁcacy and safety data by using beta distributions, the con-
ducted probabilistic sensitivity analysis has veriﬁed results found
in the base-case scenario (see Appendix II in Supplemental
Materials found at http://dx.doi.org/10.1016/j.vhri.2015.02.003).
Within the SUS perspective, the sensitivity analysis showed that
in 9991 cases the treatment with dabigatran wasmore effective, with
a higher cost, than the treatment with warfarin (quadrant 1). Only in
9 cases, treatment with dabigatran was less effective, with a higher
cost, than treatment with warfarin (quadrant 2). From the results
presented, considering a threshold equal to 3 times the GDP per
capita of 2010 per LY saved, we can consider the drug cost-effective.
Within the SSS, the sensitivity analysis showed that in 9994
cases the treatment with dabigatran was more effective, with a
higher cost, than the treatment with warfarin (quadrant 1).
Only in 6 cases, treatment with dabigatran was less effective, withEx-factory price 18% Drug presentation
191.14 US $81.34 60 units of 110 and 150 mg
24.53 US$ 10.44 30 units of 5 mg
7.83 US$ 3.33 30 units of 81 mg
228.31 US$ 97.15 28 units of 75 mg
ember/2010 [14].
Table 7 – Cost-effectiveness results.
Perspective: SUS
Dabigatran Warfarin
Cost
Total cost R$ 28,342.91 US $12,060.81 R$ 16,310.37 US $6,940.58
Drugs cost R$ 15,762.74 US $ 6,707.55 R$ 1,951.22 US $830.31
Events cost R$ 4,030.31 US $1,715.03 R$ 4,828.38 US $2,054.63
Follow-up cost R$ 8,549.87 US $3,638.24 R$ 9,530.77 US $4,055.65
Incremental cost R$ 12,032.54 US 5,120.23
Outcome
Life-years 9.42 9.11
Incremental life-years 0.30
QALY 7.25 6.91
Incremental QALY 0.35
ICER
Per life-year saved R$ 39,741 US $16,911
Per QALY gained R$ 34,867 US $14,837
Perspective: SSS
Dabigatran Warfarin
Cost
Total cost R$ 44,594.87 US $18,976.54 R$ 36,980.32 US $15,736.31
Drugs cost R$ 18,551.05 US $7,894.06 R$ 5,996.78 US $2,551.82
Events cost R$ 9,767.99 US $4,156.59 R$ 11,539.30 US $4,910.34
Follow-up costs R$ 16,275.83 US $6,925.89 R$ 19,444.25 US $8,274.15
Incremental cost R$ 7,614.55 US $3,240.23
Outcome
Life-years 9.40 9.10
Incremental life-years 0.30
QALY 7.24 6.89
Incremental QALY 0.34
ICER
Per life-year saved R$ 25,252 US $10,745
Per QALY gained R$ 22,160 US $9,430
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; SSS, Sistema de Saúde Suplementar; SUS, Sistema Único de Saúde.
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ering a threshold equal to 3 times the GDP per capita of 2010 per LY
saved, we can say that dabigatran is very cost-effective.Discussion/Conclusions
Efﬁcacy results were taken from randomized clinical trials and
systematic reviews with dabigatran and warfarin in the AF
treatment, aiming to establish the impact of different treatments
on the prevention of stroke and mortality.
Because of the chronic nature of NVAF, patients are treated on a
continuous basis for their entire lives, except for speciﬁc causes of
discontinuation. Particularly, patients who have undergone an ICH
or hemorrhagic stroke discontinue the use of anticoagulants
permanently. Patients who have undergone an extracranial hem-
orrhage may continue the treatment, discontinue the use of anti-
coagulants temporarily, or discontinue the treatment permanently.
The incidence of clinical events can lead to 1) changes in the
treatment (e.g., change in treatment or permanent or temporary
treatment discontinuation); 2) changes in a patient’s dependence
level on a caregiver owing to the stroke and ICH (independent,
moderate, or totally dependent); and 3) changes in the risk of
future events.
Within the private health care system perspective, treatment
with dabigatran is cost-effective compared with that withwarfarin, considering a threshold equal to 3 times Brazil’s GDP per
capita per QALY. Within the public health care system’s perspective,
results prove that the use of dabigatran is also cost-effective in
terms of QALY gained compared with the use of warfarin.
These results were validated through the sensitivity analysis,
which points out the inexistence of a major variance in results,
even when the limit values were tested for parameters set as
important for the result of this economic evaluation.
It is important to emphasize that results shown herein are
aligned with other cost-effectiveness evaluations of dabigatran
already performed and published for other countries. For
example, Kamel et al. [19] have performed a Markovian economic
decision model within the perspective of the US private
health care system by using clinical data from the RE-LY clinical
trial and concluded that the additional cost of the use of
dabigatran etexilate amounted to US $9000, resulting, therefore,
in an incremental cost-effectiveness ratio (ICER) of US $25,000/
QALY [19]. A similar study carried out in Canada found that
the ICER of dabigatran etexilate was CAN $10,440 per QALY
versus warfarin as per the Canadian health care system
perspective [20]. A study performed to access the situation in
Sweden has concluded that dabigatran was considered cost-
effective for the Swedish health care system, and its ICER (7742
euro per QALY) was lower than the willingness-to-pay value
normally accepted in that country [21]. A study recently carried
out in Argentina has found that dabigatran is cost-effective with
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QALY saved.
Premises are known to be required for the elaboration of
economic evaluations and likely to have a signiﬁcant impact on
the result. Because of the lack of data about the real world,
however, such premises are required and important to develop
analyses that could help decision makers take the most assertive
decision by choosing the most cost-effective therapeutic option.
This limitation is inherent to economic evaluations and is
minimized with the application of sensitivity analysis. Among
the limitations of this study we have the extrapolation of clinical
studies data to lifetime, and the use of specialists’ opinion to
fulﬁll the lack of real-world database information on the manage-
ment of treatment’s adverse events. The model used direct costs
only, and possible variation in the results if indirect cost is to be
added can be hypothesized.
Health economic analyses are effective tools to support health
decision makers and Brazilian Uniﬁed Health System ﬁnancers to
use resources in the most effective way. The contribution of this
economic model, which has used local costs and national
medical NVAF treatment guidelines, is to aid decision makers
in the task of choosing the best drug strategy for the prevention
of stroke and SE in patients with NVAF.
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